CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant

Inclusion Criteria

• •Patients must have undergone autologous transplantation for non-Hodgkin's lymphoma (NHL), Hodgkin's disease, acute myelogenous leukemia (AML), germ cell tumors, or multiple myeloma.
• •Patients must be eligible for and consent to participate in study MT1999 06 - Vaccination with tetanus toxoid and Keyhole Limpet Hemocyanin (KLH) to assess antigen specific immune responses (BB-IND 10430).
• •Patients will be eligible to receive CpG 7909 and vaccines on or after day 60 post transplant. No patients are eligible for this protocol beyond day 74 post transplant. Therefore, all patients will start therapy on this protocol between days 60-74 post transplant to allow for patient scheduling flexibility.
• •Patients must have engraftment and be independent of transfusion support or growth factor support.
• •Patients must not have received platelet or red-cell transfusions in the previous week.
• •Patients must have been continuously off all growth factors for at least 1 week.
• •Unsupported counts must be:
• •* platelets ≥ 50,000/ml
• •* Hgb ≥ 9 gm/ul
• •* Absolute neutrophil count ≥ 1000/µL
• •* Absolute lymphocyte count ≥ 500/µL
• •Patients must have a current performance status of 0-1 (Eastern Cooperative Oncology Group) or 70-100% (Karnofsky.
• •Patients must be afebrile, off antibiotics therapeutic (not prophylactic), and free of evidence of active infection. Patients must be off intravenous (IV) hyperalimentation and IV fluids.
• •Minimum laboratory values within 2 weeks of entry: Creatinine ≤ 2.0 mg/dl or CrCl ≥ 50 ml/min, Bilirubin, ALT ≤ 2 x normal
• •Age \>18 years
• •Patients receiving or scheduled to receive planned radiation therapy, growth factor therapy, or steroid therapy during the study period will be ineligible. Patients must have completed all planned post-transplant radiation therapy if applicable.
• •Patients must be able to give written informed consent and agree to comply with the study parameters
• •Patients must agree to use contraception during the study.